Insights
Search Results
Case Studies
2.24.26
How Wilson Sonsini Helped Foresight Diagnostics with Its Growth, Scale-Up, and Acquisition
Foresight Diagnostics is a leading cancer diagnostics company founded in 2020 and spun out of Stanford University. Foresight has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease that is significantly more sensitive than existing tests. Its technology, called PhasED-SeqTM, is based on a simple blood draw and next-generation sequencing. It is broadly applicable to a variety of cancers, and its ability to detect circulating tumor DNA at levels of 0.0001 percent (or one part-per-million) has the potential to provide actionable information to physicians and biopharmaceutical companies, thus enabling the development of a more proactive and personalized treatment approach.
Newsletters
1.07.26
The Life Sciences Report – January 2026
This latest edition features articles on reasons for optimism around 2026 life sciences fundraising, key IP priorities for biotech and biopharma following Series B financing, the default rules of joint patent rights worldwide, the evolving role of innovation theories of harm in the antitrust analysis of life science mergers, life sciences venture financings for firm clients across 2H2024 and 1H2025, and how Wilson Sonsini helped ensure Light Horse Therapeutics’ impressive debut. The report also includes details on the most recent Biotech Summit and Phoenix Conference, the LaunchBio East Coast NextGen VC Forum, the latest episodes of the NextGen VC Podcast focused on life sciences investing, and the Patents and Innovations Library for in-house IP counsel, as well as select life sciences client highlights and upcoming events.
Newsletters
6.03.25
The Life Sciences Report – June 2025
This latest edition features articles on succeeding in the current life sciences funding market, strategic and legal considerations in digital health combinations, the corporate practice of medicine and guidance for healthcare companies and investors, the FDA’s plan to phase out animal testing, and life sciences venture financings for clients in 2024. The newsletter also includes details on the firm’s additions of leading digital health attorney and former HHS policymaker Jodi Daniel and USPTO veteran Jean Witz, the recent LaunchBio West Coast NextGen VC Forum and Life Sciences Investment Forum, Wilson Sonsini’s LSPN “Life Sciences IP Firm of the Year” award and sponsorship of the National Inventors Hall of Fame Induction Ceremony, the latest episodes of the NextGen VC Podcast focused on life sciences investing, and the Patents and Innovations Learning Library for in-house IP counsel, as well as select life sciences client highlights, recent webinars, and upcoming events.
Alerts
4.03.25
FDA’s LDT Final Rule Rejected by Federal District Court in Texas
As Wilson Sonsini previously reported,1 the U.S. Food and Drug Administration (FDA) had been preparing the industry to comply with the 2024 LDT Final Rule, which phases out the FDA’s enforcement discretion policy for laboratory developed tests (LDTs) and phases in device requirements starting in May 2025. But legal challenges against the LDT Final Rule have prevailed. On March 31, 2025, the U.S. District Court for the Eastern District of Texas vacated the LDT Final Rule, declaring that LDTs are not devices regulated by the FDA under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Rather, the court determined that LDTs are professional services regulated by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).
Newsletters
1.08.25
The Life Sciences Report – January 2025
This latest edition features an interview with retiring longtime Wilson Sonsini IP partner Vern Norviel and articles on MedTech and pharma trends for 2025, the eligibility of life sciences companies for qualified small business stock, what life sciences companies need to know about brands, double-patenting jeopardy, and life sciences venture financings for clients across 2H 2023 and 1H 2024. The newsletter also includes details on the firm’s inaugural Biotech Summit and 29th Annual Phoenix Conference, technical writing and IPO documentation offerings for life sciences clients, 2024 LaunchBio NextGen VC Forums, the Patents and Innovations Learning Library for in-house IP counsel, the latest episodes of the NextGen VC Podcast focused on life sciences investing, and a call for applications from MedTech Innovator and BioTools Innovator, as well as select life sciences client highlights.
Newsletters
6.10.24
The Life Sciences Report – June 2024
This latest edition features articles on biotech client Siolta Therapeutics, the use of safety and efficacy findings to extend drug exclusivity periods, life sciences venture financings for clients in 2023, and updated USPTO guidance for determining non-obviousness. The newsletter also includes details on the recent LaunchBio NextGen VC Forum in San Francisco, the firm’s Patents and Innovations Learning Library for in-house IP counsel, the latest episodes of the LaunchBio/Wilson Sonsini NextGen VC Podcast focused on life sciences investing, and the firm’s sponsorship of the National Inventors Hall of Fame Induction Ceremony, as well as select life sciences client highlights.
Newsletters
1.04.24
The Life Sciences Report – January 2024
This issue features articles on the firm’s Business Advisory Practice supporting Nervosave Therapeutics’ U.S. expansion; the USPTO’s forthcoming guidance on AI innovation protection; option pool sizes for life sciences companies; life sciences venture financings for clients in 2H 2022 and 1H 2023; and Congress’s attempts to improve medical diagnostics patent eligibility. It also includes a client interview with SonoThera CEO Kenneth Greenberg, an article on DOJ’s incentives for life sciences companies to self-disclose misconduct, and a Q&A with Ed Shenkan on decreasing risk from medical device concept to commercialization, as well as details on recent life sciences-focused NextGen VC Forums hosted by Wilson Sonsini and LaunchBio, the 28th annual Phoenix Conference and 2023 Life Sciences Investment Forum, and select life sciences client highlights.
Client Highlights
4.28.23
Wilson Sonsini Advises Foresight Diagnostics on $58.75 Million Series B
On April 27, 2023, Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced the close of an oversubscribed Series B financing round of $58.75 million. The financing was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University, and The University of Colorado Healthcare Innovation Fund. Wilson Sonsini Goodrich & Rosati advised Foresight on corporate, IP, licensing, and business advisory matters related to the transaction.
Press Releases
6.04.19
Matthew J. Meyer Joins Wilson Sonsini's Life Sciences Practice
- Meyer to lead development of firm's life science business advisory practice—brings extensive start-up and established biopharma, med tech and diagnostic commercial, business development and strategic experience to role -